KIR3DL1 and cancer: Some of the first evidence that blocking KIR function could improve cancer outcomes came from hematopoietic stem cell transplants in leukemia patients where there was a KIR:HLA repertoire mismatch – patients receiving transplants with an alloreactive NK cell population showed improved disease-free survival rates and reduced rate of relapse15,16.